GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates

GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update

GenSight Biologics Launches Newsletter for Retail Investors

GenSight Biologics renegotiates financial obligations and provides operational updates

GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings

GenSight Biologics Appoints William Monteith to its Board of Directors

GenSight Biologics announces the availability of a prospectus in connection with the listing of new shares on Euronext Paris

GenSight Biologics announces a successful offering for an amount over €9.2 million

GenSight Biologics Announces the Filing of its 2023 Universal Registration Document

GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update